Regulated Information

Filter

Period

Filter by

Reset

Showing: 1 – 05 of 152 Regulated Information

Show

Sort

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

– 07 December 2023

07 December 2023

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

– 07 December 2023

07 December 2023

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

PARIS, FRANCE, 07 December 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational elafibranor. An oral, once-daily…

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

– 07 December 2023

07 December 2023

Capital Markets Day 2023 – Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

PARIS, FRANCE, 7 December 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K.